Legal uncertainty in the area of genetic diagnostic testing

Nature Biotechnology

Volumn 27, Issue 10, 2009, Pages 903-909

  Huys, Isabelle ^a   Berthels, Nele ^a   Matthijs, Gert ^a   Van Overwalle, Geertrui ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; COLON CANCER; DATA ANALYSIS; DIAGNOSTIC TEST; EUROPE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FAMILIAL CANCER; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; LEGAL ASPECT; LICENSING; OVARY CANCER; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EUROPEAN UNION; GENETIC DISEASES, INBORN; GENETIC TESTING; HUMANS; PATENTS AS TOPIC; UNITED STATES;

EID: 70349959707     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1009-903     Document Type: Review

References (31)

1. Gold, R.E. & Carbone, J. Myriad Genetics: In the Eye of the Policy Storm. A Case Study for The International Expert Group On Biotechnology, Innovation And Intellectual Property (The Innovation Partnership, Montreal, Canada, 2008).
2. Barton, J.H. Nat. Biotechnol. 24, 939-941 (2006).
3. Gaisser, S., Hopkins, M.M., Liddell, K., Zika, E. & Ibaretta, D. Nature 458, 407-408 (2009).
4. van Overwalle, G., van Zimmeren, E., Verbeure, B. & Matthijs, G. Nat. Rev. Genet. 7, 143-148 (2006).
5. Hopkins, M.M., Mahdi, S., Patel, P. & Thomas, S.T. Nat. Biotechnol. 25, 185-187 (2007).
6. Jensen, K. & Murray, F. Science 310, 239-240 (2005).
7. Verbeure, B. & Matthijs, G. & Van Overwalle, G. Eur. J. Hum. Genet. 14, 26-33 (2006).
8. Walsh, J.P., Cho, C. & Cohen, W.M. Science 309, 2002-2003 (2005)
9. Holman, C.M. UMKC Law Rev. 76, 295 (2007).
10. Caulfield, T., Cook-Deegan, R.M., Scott Kieff, F. & Walsh, J.P. Nat. Biotechnol. 24, 1091-1094 (2006).
11. Gold, R.E. et al. Towards a New Era of Intellectual Property: From Confrontation to Negotiation (The Innovation Partnership and McGill Centre for Intellectual Property Policy, Monteal, 2008).
12. Holman, CM. Science 322, 198-199 (2008).
13. Stott, M. & Valentine, J. Nat. Biotechnol. 21, 729-731 (2003).
14. Cho, M.K., Illangasekare, S., Weaver, M.A., Leonard, D.G. & Merz, J.F. J. Mol. Diagn. 5, 3-8 (2003).
15. Verbeure, B., Matthijs, G. & van Overwalle, G. Eur. J. Hum. Genet. 14, 26-33 (2006).
16. Aymé, S. Eur. J. Hum. Genet. 16, 405-411 (2008)
17. Markman v. Westview Instruments, Inc., 52 F. 3d 967 (Fed. Cir. 1995)
18. van Zimmeren, E., Vanneste, S. & Van Overwalle, G. Patent Licensing in Medical Biotechnology in Europe, Leuven (2009).
19. Matthijs, G. Fam. Cancer 5, 95-102 (2006).
20. Technical Board of Appeal maintains two Myriad/ breast cancer patents in limited form, website EPO (news), 19 November 2008. Epoline (www.epoline.org).
21. Myriad Genetics and Oncormed, filed Dec. 2, 1997, D.C. Utah, Doc. No.2:97cv922B.
22. Myriad Genetics, Inc. and the University of Pennsylvania, filed Nov. 19, 1998, D.C. Utah, Doc. No.2:98cv829.
23. Holman, CM. Science 322, 198-199 (2008).
24. US Utility Patent Examination Guidelines. http://www. uspto.gov/web/offices/pac/utility/utilityguide.pdf Prometheus Labs v. Mayo Collaborative 2008 WL 878910 (S.D. Cal. March 28 2008).
25. Simmons, W.J. Nat. Biotechnol. 27, 245-248 (2009).
26. Patent reform urged at AIPPI. Managing IP 17 (October 2008) Amgen v. Chugai Pharmaceutical Co., (927 F.2d 1200 (Fed. Cir. 1991)).
27. Directive 98/44/EC of 6 July 1998 of the European Parliament and of the Council on the legal protection of biotechnological inventions. Official Journal EPO L213/13-L213/21 (30 July 1998).
28. G1/04-Diagnostic methods, 16 December 2005, Official Journal EPO, 334 (2006).
29. Laboratory Corporation of America Holdings v. Metabolite Laboratories, Inc., June 22, 370 F.3d 1354 (2006).
30. van Overwalle, G. Gene Patents and Public Health, Setting the Scene (Bruylant, Belgium, 2007).
31. OECD. OECD Guidelines for Licensing of Genetic Inventions (OECD, Paris, 2006).